Hsieh Tung-Sheng, Wu Jhen-Yi, Chang Cheng-Chung
Graduate Institute of Biomedical Engineering, National Chung Hsing University, 250 Kuo Kuang Road, Taichung 402, Taiwan (R.O.C.).
Chemistry. 2014 Jul 28;20(31):9709-15. doi: 10.1002/chem.201402285. Epub 2014 Jul 2.
A new class of near-infrared (NIR)-absorptive (>900 nm) photosensitizer based on a phenothiazinium scaffold is reported. The stable solid compound, o-DAP, the oxidative form of 3,7-bis(4-methylaminophenyl)-10H-phenothiazine, can generate reactive oxygen species (ROS, singlet oxygen and superoxide) under appropriate irradiation conditions. After biologically evaluating the intracellular uptake, localization, and phototoxicity of this compound, it was concluded that o-DAP is photostable and a potential selective photodynamic therapy (PDT) agent under either NIR or white light irradiation because its photodamage is more efficient in cancer cells than in normal cells and is without significant dark toxicity. This is very rare for photosensitizers in PDT applications.
报道了一类基于吩噻嗪鎓支架的新型近红外(NIR)吸收(>900 nm)光敏剂。稳定的固体化合物o-DAP,即3,7-双(4-甲基氨基苯基)-10H-吩噻嗪的氧化形式,在适当的辐照条件下可产生活性氧(ROS,单线态氧和超氧阴离子)。在对该化合物的细胞内摄取、定位和光毒性进行生物学评估后,得出结论:o-DAP在近红外或白光照射下具有光稳定性,是一种潜在的选择性光动力疗法(PDT)药物,因为其对癌细胞的光损伤比对正常细胞更有效,且无明显暗毒性。这在光动力疗法应用中的光敏剂中非常罕见。